Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”

Abstract

PolyADP ribose polymerase inhibitors (PARPi) have transformed the treatment of ovarian cancer. Particularly in high-grade serous ovarian cancer (HGSOC), a disease characterized by homologous recombination deficiency (HRD), PARPi have had a rapid and profound impact on the disease course, as well as biologic and biomarker definitions of HGSOC, thereby creating a paradigm shift in the approach to treatment. In this review, we discuss the role of PARPi in the maintenance treatment of HGSOC, its effect on platinum sensitivity, and cross-resistance between platinum and PARP inhibitors.

Keywords

PARP inhibitors / olaparib / niraparib / ovarian cancer / maintenance therapy

References

[1] Markman M,Hakes T.Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.J Clin Oncol1991;9:389-93

[2] Friedlander M,Tinker A.Gynecologic Cancer InterGroupClinical trials in recurrent ovarian cancer.Int J Gynecol Cancer2011;21:771-5

[3] Hanker LC,Burchardi N.AGO and GINECO study groupThe impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy.Ann Oncol2012;23:2605-12

[4] Lindemann K,Mapagu C.Australian Ovarian Cancer Study GroupResponse rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.Gynecol Oncol2018;150:239-46

[5] Wagner U,Largillier R.Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.Br J Cancer2012;107:588-91 PMCID:PMC3419956

[6] Matsuo K,Roman LD.Overcoming platinum resistance in ovarian carcinoma.Expert Opin Investig Drugs2010;19:1339-54 PMCID:PMC2962713

[7] Bryant HE,Thomas HD.Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.Nature2005;434:913-7

[8] Fong PC,Yap TA.Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.N Engl J Med2009;361:123-34

[9] Kaufman B,Schmutzler RK.Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.J Clin Oncol2015;33:244-50 PMCID:PMC6057749

[10] Swisher EM,Oza AM.Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.The Lancet Oncology2017;18:75-87

[11] Kristeleit R,Burris HA.A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline.BRCA1/223:4095-106

[12] Moore KN,Geller MA.Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.The Lancet Oncology2019;20:636-48

[13] Pujade-lauraine E,Selle F.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.The Lancet Oncology2017;18:1274-84

[14] Coleman RL,Lorusso D.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2017;390:1949-61. PMCID:PMC5901715

[15] Mirza MR,Herrstedt J.ENGOT-OV16/NOVA InvestigatorsNiraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.N Engl J Med2016;375:2154-64

[16] Markman M,Moon J.Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.Gynecol Oncol2009;114:195-8 PMCID:PMC2744303

[17] Pecorelli S,Gadducci A.After 6 Italian Cooperative GroupPhase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.J Clin Oncol2009;27:4642-8

[18] Pfisterer J,Reuss A.AGO-OVAR, GINECO. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.J Natl Cancer Inst2006;98:1036-45

[19] Tewari KS,Enserro D.Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer.J Clin Oncol2019;37:2317-28 PMCID:PMC6879307

[20] Moore K,Scambia G.Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.N Engl J Med2018;379:2495-505

[21] Ray-Coquard I,Pignata S.PAOLA-1 InvestigatorsOlaparib plus bevacizumab as first-line maintenance in ovarian cancer.N Engl J Med2019;381:2416-28

[22] González-Martín A,Vergote I.PRIMA/ENGOT-OV26/GOG-3012 InvestigatorsNiraparib in patients with newly diagnosed advanced ovarian cancer.N Engl J Med2019;381:2391-402

[23] Bartoletti M,Musacchio L,Puglisi F.Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices.ESMO Open2021;6:100135 PMCID:PMC8100608

[24] Cecere SC,Salutari V.Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.Gynecol Oncol2020;156:38-44

[25] Frenel J,Berton-rigaud D.813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial.Annals of Oncology2020;31:S615

[26] Lheureux S,Garg S.EVOLVE: A multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression.Clin Cancer Res2020;26:4206-15

[27] Swisher EM,Oza AM.Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).Nat Commun2021;12:2487 PMCID:PMC8093258

[28] Wang Y,Cruz C.kConFab InvestigatorsThe BRCA1-Δ11q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin.Cancer Res2016;76:2778-90 PMCID:PMC4874568

[29] Hurley RM,Visscher DW.53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.Gynecol Oncol2019;153:127-34 PMCID:PMC6430710

[30] Christie EL,Beach J.Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer.Nat Commun2019;10:1295 PMCID:PMC6426934

[31] Essel KG,Lai T.PARPi after PARPi in epithelial ovarian cancer.Gynecol Oncol Rep2021;35:100699 PMCID:PMC7840844

[32] Wilson MK,Aoki D.participants of the Fifth Ovarian Cancer Consensus ConferenceFifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.Ann Oncol2017;28:727-32 PMCID:PMC6246494